The trading price of Ocular Therapeutix Inc. (NASDAQ:OCUL) closed higher on Tuesday, May 23, closing at $6.95, 6.76% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $6.7601 and $7.32. In examining the 52-week price action we see that the stock hit a 52-week high of $6.86 and a 52-week low of $2.57. Over the past month, the stock has gained 12.10% in value.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Ocular Therapeutix Inc., whose market valuation is $531.26 million at the time of this writing, is expected to release its quarterly earnings report May 08, 2023. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.28 per share this quarter, however they have predicted annual earnings per share of -$1.15 for 2023 and -$0.94 for 2024. It means analysts are expecting annual earnings per share growth of -18.60% this year and 18.30% next year.
Analysts have forecast the company to bring in revenue of $14.36 million for the current quarter, with the likely lows of $13.8 million and highs of $15 million. The average estimate suggests sales will likely up by 17.10% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2023 is $58.51 million. The company’s revenue is forecast to grow by 13.60% over what it did in 2023.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Ocular Therapeutix Inc. No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest OCUL has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned OCUL a recommendation rating is 8. Out of them, 1 rate it a Hold, while 6 recommend Buy, whereas 1 assign an Overweight rating. 0 analyst(s) have tagged Ocular Therapeutix Inc. (OCUL) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that OCUL’s price is currently 11.21% off the SMA20 and 22.74% off the SMA50. The RSI metric on the 14-day chart is currently showing 69.45, and weekly volatility stands at 4.56%. When measured over the past 30 days, the indicator reaches 5.16%. Ocular Therapeutix Inc. (NASDAQ:OCUL)’s beta value is currently sitting at 1.29, while the Average True Range indicator is currently displaying 0.35. With analysts defining $8.00-$18.00 as the low and high price targets, we arrive at a consensus price target of $12.75 for the trailing 12-month period. The current price is about -15.11% off the estimated low and -158.99% off the forecast high, based on this estimate. Investors will be thrilled if OCUL’s share price rises to $13.00, which is the median consensus price. At that level, OCUL’s share price would be -87.05% below current price.
To see how Ocular Therapeutix Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: OCUL stock’s performance was 6.76% in the latest trading, and 107.46% in the past year, while KalVista Pharmaceuticals Inc. (KALV) has traded 0.00% on the day and positioned 17.18% higher than it was a year ago. Another comparable company Anika Therapeutics Inc. (ANIK) saw its stock close 0.19% higher in the most recent trading session but was up 28.84% in a year. Also in last trading session, the S&P 500 Index has plunged -1.12%, while the Dow Jones Industrial also saw a negative session, down -0.69% on the day.
An evaluation of the daily trading volume of Ocular Therapeutix Inc. (NASDAQ:OCUL) indicates that the 3-month average is 971.30K. However, this figure has increased over the past 10 days to an average of 1.11 million.
Currently, records show that 77.39 million of the company’s shares remain outstanding. The insiders hold 0.10% of outstanding shares, whereas institutions hold 56.60%. The stats also highlight that short interest as of Apr 27, 2023, stood at 4.84 million shares, resulting in a short ratio of 5.25 at that time. From this, we can conclude that short interest is 6.25% of the company’s total outstanding shares. It is noteworthy that short shares in April were up slightly from the previous month’s figure, which was 4.6 million. However, since the stock’s price has seen 147.33% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
